Literature DB >> 11523608

Holter monitoring in AL amyloidosis: prognostic implications.

G Palladini1, G Malamani, F Cò, A Pistorio, F Recusani, E Anesi, P Garini, G Merlini.   

Abstract

The heart is involved in more than one third of patients with primary (AL) amyloidosis at diagnosis and it is by far the most common cause of death. Rhythm and conduction abnormalities generally represent the terminal event. The aims of this study were to determine the spectrum of Holter abnormalities found in AL amyloidosis and to assess their prognostic significance, particularly in relation to sudden death. Fifty-one patients with AL amyloidosis were included, and all of them had a complete history, physical examination, two-dimensional echocardiography, and 24-hour Holter monitoring. Fifty-five percent of these patients had echographic signs of heart involvement and 23% had heart failure. Complex ventricular arrhythmias were found in 57% of patients, couplets in 29%, and nonsustained ventricular tachycardia in 18%. Overall median survival was 23.4 months. Congestive heart failure, echocardiographic abnormalities, and Holter abnormalities adversely affected survival. The multivariate analysis demonstrated that interventricular septum thickness and couplets were independent predictors of survival. The presence of couplets correlated with sudden death. Holter monitoring may contribute to assessing the prognosis of patients with AL amyloidosis.

Entities:  

Mesh:

Year:  2001        PMID: 11523608     DOI: 10.1046/j.1460-9592.2001.01228.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  15 in total

1.  Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

Authors:  Giovanni Palladini; Paolo Milani; Andrea Foli; Laura Obici; Francesca Lavatelli; Mario Nuvolone; Riccardo Caccialanza; Stefano Perlini; Giampaolo Merlini
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

2.  A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

Authors:  Giovanni Palladini; Paola Russo; Paolo Milani; Andrea Foli; Francesca Lavatelli; Mario Nuvolone; Stefano Perlini; Giampaolo Merlini
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

3.  Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor.

Authors:  Arnt V Kristen; Johannes Rinn; Ute Hegenbart; David Lindenmaier; Corina Merkle; Christoph Röcken; Stefan Hardt; Evangelos Giannitsis; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2014-10-21       Impact factor: 5.460

4.  Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis.

Authors:  Ketna S Patel; Philip N Hawkins; Carol J Whelan; Julian D Gillmore
Journal:  BMJ Case Rep       Date:  2014-12-22

Review 5.  Cardiac amyloidosis: shifting our impressions to hopeful.

Authors:  Douglas B Sawyer; Martha Skinner
Journal:  Curr Heart Fail Rep       Date:  2006-06

6.  Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021.

Authors:  Marcus V Simões; Fabio Fernandes; Fabiana G Marcondes-Braga; Philip Scheinberg; Edileide de Barros Correia; Luis Eduardo P Rohde; Fernando Bacal; Silvia Marinho Martins Alves; Sandrigo Mangini; Andréia Biolo; Luis Beck-da-Silva; Roberta Shcolnik Szor; Wilson Marques Junior; Acary Souza Bulle Oliveira; Márcia Waddington Cruz; Bruno Vaz Kerges Bueno; Ludhmila Abrahão Hajjar; Aurora Felice Castro Issa; Felix José Alvarez Ramires; Otavio Rizzi Coelho Filho; André Schmidt; Ibraim Masciarelli Francisco Pinto; Carlos Eduardo Rochitte; Marcelo Luiz Campos Vieira; Cláudio Tinoco Mesquita; Celso Dario Ramos; José Soares-Junior; Minna Moreira Dias Romano; Wilson Mathias Junior; Marcelo Iório Garcia Junior; Marcelo Westerlund Montera; Marcelo Dantas Tavares de Melo; Sandra Marques E Silva; Pedro Manoel Marques Garibaldi; Aristóteles Comte de Alencar Neto; Renato Delascio Lopes; Diane Xavier de Ávila; Denizar Viana; José Francisco Kerr Saraiva; Manoel Fernandes Canesin; Glaucia Maria Moraes de Oliveira; Evandro Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2021-09       Impact factor: 2.000

7.  Focal monomorphic ventricular tachycardia as the first manifestation of amyloid cardiomyopathy.

Authors:  Srikanth Seethala; Sandeep Jain; N Paul Ohori; Sara Monaco; Joan Lacomis; Frederick Crock; Jan Nemec
Journal:  Indian Pacing Electrophysiol J       Date:  2010-03-05

Review 8.  [Risk stratification and treatment of cardiac amyloidoses].

Authors:  A V Kristen; S O Schönland; A Remppis; U Hegenbart; P A Schnabel; H A Katus; T J Dengler
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

9.  Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.

Authors:  G Palladini; P Milani; A Foli; M Vidus Rosin; M Basset; F Lavatelli; M Nuvolone; L Obici; S Perlini; G Merlini
Journal:  Leukemia       Date:  2014-07-25       Impact factor: 11.528

10.  Cardiac amyloidosis presenting with recurrent ischaemic strokes.

Authors:  Suleiman Suleiman; John Joseph Coughlan; David Moore
Journal:  BMJ Case Rep       Date:  2020-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.